Skip to main content

Peer Review reports

From: Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series

Original Submission
3 Feb 2022 Submitted Original manuscript
14 Mar 2022 Reviewed Reviewer Report
31 Mar 2022 Reviewed Reviewer Report
2 May 2022 Author responded Author comments - Li Zhuo
Resubmission - Version 2
2 May 2022 Submitted Manuscript version 2
7 May 2022 Author responded Author comments - Li Zhuo
Resubmission - Version 3
7 May 2022 Submitted Manuscript version 3
22 May 2022 Author responded Author comments - Li Zhuo
Resubmission - Version 4
22 May 2022 Submitted Manuscript version 4
2 Jun 2022 Reviewed Reviewer Report
9 Jun 2022 Reviewed Reviewer Report
24 Jun 2022 Reviewed Reviewer Report
29 Jun 2022 Author responded Author comments - Li Zhuo
Resubmission - Version 5
29 Jun 2022 Submitted Manuscript version 5
10 Jul 2022 Reviewed Reviewer Report
3 Aug 2022 Reviewed Reviewer Report
24 Sep 2022 Author responded Author comments - Li Zhuo
Resubmission - Version 6
24 Sep 2022 Submitted Manuscript version 6
15 Oct 2022 Author responded Author comments - Li Zhuo
Resubmission - Version 7
15 Oct 2022 Submitted Manuscript version 7
17 Oct 2022 Author responded Author comments - Li Zhuo
Resubmission - Version 8
17 Oct 2022 Submitted Manuscript version 8
7 Nov 2022 Reviewed Reviewer Report
23 Nov 2022 Reviewed Reviewer Report - Roberto Padoan
26 Nov 2022 Reviewed Reviewer Report
22 Dec 2022 Author responded Author comments - Li Zhuo
Resubmission - Version 9
22 Dec 2022 Submitted Manuscript version 9
27 Jan 2023 Author responded Author comments - Li Zhuo
Resubmission - Version 10
27 Jan 2023 Submitted Manuscript version 10
Publishing
31 Jan 2023 Editorially accepted
8 Feb 2023 Article published 10.1186/s12882-023-03075-8

You can find further information about peer review here.

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us